DPM1-CDG (DPM1-Congenital Disorder of Glycosylation) is a rare genetic disorder caused by a mutation in the DPM1 gene. It is characterized by a wide range of symptoms, including developmental delays, intellectual disability, seizures, and movement disorders. It is inherited in an autosomal recessive pattern.

The symptoms of DPM1-CDG vary from person to person, but may include:

-Developmental delays
-Intellectual disability
-Seizures
-Feeding difficulties
-Growth delays
-Hearing loss
-Vision problems
-Movement disorders
-Gastrointestinal issues
-Skin abnormalities
-Heart defects
-Kidney problems
-Skeletal abnormalities

DPM1-CDG is caused by mutations in the DPM1 gene. These mutations lead to a deficiency in the enzyme dolichol-phosphate mannosyltransferase 1, which is involved in the synthesis of glycoproteins. This deficiency results in a wide range of symptoms, including developmental delays, intellectual disability, seizures, and movement disorders.

Currently, there is no cure for DPM1-CDG. Treatment focuses on managing the symptoms and complications of the condition. This may include physical therapy, occupational therapy, speech therapy, and nutritional support. Medications may also be prescribed to help manage seizures, gastrointestinal issues, and other symptoms. In some cases, surgery may be recommended to correct certain physical abnormalities.

The risk factors for DPM1-CDG include:

1. Family history of the disorder
2. Mutation in the DPM1 gene
3. Consanguinity (marriage between close relatives)
4. Advanced maternal age
5. Exposure to certain environmental toxins or medications during pregnancy.

At this time, there is no cure for DPM1-CDG. However, there are medications that can help manage the symptoms of the disorder. These medications include anticonvulsants, muscle relaxants, and anti-inflammatory drugs. Additionally, physical and occupational therapy can help improve mobility and coordination.